ArcherDx blood Cancer research tests detect various driver mutations in hematologic malignancies, such as myeloid and lymphoid diseases, by targeted next-generation sequencing (NGS). This approach combines FusionPlex® and VariantPlex® panels to characterize gene fusions, point mutations, copy number variations (CNVs) and other variant types from a single sample. The different blood cancer based panels from ArcherDx includes: